is saxagliptin a glp 1 Incretin axis and incretin-based therapies: GLP-1 produced by the Saxagliptin is a DPP-4 Inhibitor

While these approaches help many people, a significant percentage find themselves managing chronic symptoms despite trying multiple interventions

Dosing varies by protocol

In April 2025, the company discontinued its main obesity candidate, danuglipron, due to safety concerns

PlexusDx recommends discussing your breastfeeding timeline with your care team before starting any weight loss medication

Similarly, the MD was consistently associated with a reduced risk of T2D across genders, with females showing improvements in insulin resistance and glucose metabolism, while males more often benefited from reductions in BW and BMI

Ozempic for type 2 diabetes typically qualifies without extra documentation, while weight loss use may require additional approval